In Front of Cancer: Advancing Multiple Myeloma Treatment

How is Johnson & Johnson Innovative Medicine advancing the fight against Multiple Myeloma, the second most common blood cancer in Europe? Hear about the significant improvements in treatment, the latest survival statistics from Ireland, and our longstanding commitment to developing innovative therapies.
Click here to learn more.www.janssenmed...